Lipid-lowering agents and their meaning in the treatment of the fat metabolism-atherosclerosis functional circle.
The clinical pharmacology of lipid-lowering agents and their meaning in the treatment of the fat metabolism-atherosclerosis functional circle are described. All the aspects associated with these important problems are carefully analyzed and the possible consequences for their rational use are interpreted. The current view of the actual situation in this field is presented and the trends in the development of prophylactic and therapeutic treatment with lipid-lowering agents in the fat metabolism-atherosclerosis functional circle are shown. Epidemiologic considerations complement these reflections.
D001161:Arteriosclerosis / Q000145:classification / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D001711:Biotransformation; D005223:Fats / Q000378:metabolism*; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007408:Intestinal Absorption / Q000187:drug effects; D008074:Lipoproteins / Q000378:metabolism; D012306:Risk
D005223:Fats; D000960:Hypolipidemic Agents; D008074:Lipoproteins